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Background: Plasmodium vivax has the potential to infect 2.85 billion individuals worldwide. Nevertheless, the
limited number of studies investigating the immune status of individuals living in malaria-endemic areas, as well as
the lack of reports investigating serological markers associated with clinical protection, has hampered development
of vaccines for P. vivax. It was previously demonstrated that naturally total IgG against the N-terminus of P. vivax
merozoite surface protein 1 (Pv-MSP1) was associated with reduced risk of malarial infection.
Methods: Immune response against Pv-MSP1 (N-terminus) of 313 residents of the Rio Pardo rural settlement
(Amazonas State, Brazil) was evaluated in a cross-sectional and longitudinal follow up over two months (on site)
wherein gold standard diagnosis by thick blood smear and rRNA gene-based nested real-time PCR were used to
discriminate symptomless Plasmodium vivax-infected individuals who did not develop clinical symptoms during a
2-months from those uninfected ones or who have had acute malaria. The acquisition of antibodies against
Pv-MSP1 was also evaluated as survival analysis by prospective study over a year collecting information of new
malaria infections in surveillance database.
Results: The majority of P. vivax-infected individuals (52-67%) showed immune recognition of the N-terminus of
Pv-MSP1. Interesting data on infected individuals who have not developed symptoms, total IgG levels against the
N-terminus Pv-MSP1 were age-dependent and the IgG3 levels were significantly higher than levels of subjects had
acute malaria or those uninfected ones. The total IgG anti ICB2-5 was detected to be an important factor of
protection against new malaria vivax attacks in survival analysis in a prospective survey (p = 0.029).
Conclusions: The study findings illustrate the importance of IgG3 associated to 2-months of symptomless in
P. vivax infected individuals and open perspectives for the rationale of malaria vaccine designs capable to sustain
high levels of IgG3 against polymorphic malaria antigens.
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Plasmodium vivax is the most widespread species of hu-
man malaria parasite, and risk of P. vivax infection is
higher compared to Plasmodium falciparum [1,2]. In
Brazil, 99.8% of malaria cases are concentrated in the
Amazon region with P. vivax being the most prevalent
species (ca 85%) [3]. Although P. vivax is currently as-
sociated with non-life-threatening malarial infection,
recent studies have reported similar complications and
pathogenic mechanisms frequently observed in malaria
caused by P. falciparum [4-6]. Drug resistance to com-
monly used anti-malarial drugs has also been reported
worldwide [4,7-16] challenging the current view of P.
vivax as a less harmful parasite and raising the need for
developing an effective vaccine.
In hopes of reducing malaria morbidity and mortality,
Plasmodium merozoite antigens have been proposed as
targets for vaccine design [2]. Amongst this family of
molecules, merozoite surface protein-1 (MSP1) is a
195-kDa glycoprotein abundant on the surface of mero-
zoites and essential for merozoite development due to
its involvement in erythrocyte invasion [17]. MSP1 at-
taches to the parasite membrane by a GPI anchor and
associates with other merozoite molecules (e g, MSP6
and MSP7), forming a multicomplex protein [18]. MSP1
displays a highly polymorphic N-terminus, yet a con-
served C-terminus region [17,19,20]. The Pvmsp1 gene
consists of six highly polymorphic domains (called poly-
morphic blocks) flanked by fairly conserved sequences
(two, four and five blocks) [19] as interspecies conserved
blocks called ICBs [20] and one conserved domain (CB-3).
Many studies have indicated that MSP1 is highly im-
munogenic in natural malarial infections and often asso-
ciated with parasite exposure [21-26]. As such, it has
considerable potential as a candidate target for vaccine
design and/or clinical trials [27-32]. Although short-
lived, P. vivax MSP1 (referred to as Pv-MSP1) humoral
immune response has been shown to be mostly against
the polymorphic domains [27,28,33-35]. In individuals
clinically protected from malaria, high levels of anti-
bodies against a polymorphic domain in the N-terminus
of Pv-MSP1 [30].
The current study identified occurrence of symptom-
less Plasmodium vivax-infected individuals during a
two-months follow-up at the Rio Pardo rural settlement
(Amazonas State, Brazil), and performing humoral
immune response analysis (total IgG and subclasses)
against Pv-MSP1.
Methods
Selected area and population
At the Rio Pardo rural settlement (Figure 1) an agricul-
tural settlement of Rio Pardo, Presidente Figueiredo mu-
nicipality, in the northeast region of Amazonas State,Brazil. The rural community of Rio Pardo is located
roughly 160 km from Manaus, the capital of the state.
Main access is via a paved road (BR-174) that connects
the states of Amazonas and Roraima. These unpaved
roads have a main road that is connected perpendicu-
larly to multiple side roads that are surrounded by trop-
ical rain forest. The area of Rio Pardo consists of six side
roads (eclipse). The settlement also includes a riverine
community, where inhabitants live 1.5 km from the Rio
Pardo stream margins. Inhabitants rely on subsistence
farming and fishing along the Rio Pardo stream. The an-
nual mean temperature was 31°C and average annual
rainfall was 2,000 mm per year. Housing quality is poor,
thereby rendering ineffective indoor residual spraying of
insecticides against the mosquito vectors of malaria. De-
forestation is common, although decreasing production
has been faced in exploration areas. Health care access is
extremely limited in the area, and only one health centre
handles all diagnoses of suspected malaria cases by
means of Giemsa-stained thick blood smears.
In a census conducted from September to October
2008, five hundred nineteen inhabitants were identified,
of which 51.4% lived along unpaved roads organized in a
‘fishbone’ pattern (a typical deforestation pattern for
Amazon settlements) [36] and 48.6% lived in the Igarapé
area located 1.5 km from the stream margins of the
riverine community. Annual Parasitemic Index related
to P. vivax was similar in both areas during the study
period (Figure 1). Twenty individuals were excluded
from the study due to double registration and one hun-
dred eighty six samples were discarded due to poor
DNA extraction or absence of serum samples. After ap-
plying these exclusion criteria, 313 individuals were in-
cluded in the study (Figure 2).
Study design
In November 2008, a cross-sectional study was per-
formed in order to collect blood samples to determine
malarial infection by Giemsa-stained blood thick smears
and real-time PCR and for serological studies to evaluate
humoral responses of individuals of the riverine com-
munity. At this time, a standardized questionnaire con-
taining demographic, clinical and epidemiological data
(number of previous malaria episodes, presence of signs
and symptoms) was applied by trained and calibrated in-
terviewers. After that, a longitudinal follow up (on site)
was performed over two months and the participants
continued to be interviewed and examined. Based on the
results of Giemsa-stained thick blood smears obtained at
cross sectional, the participants were initially classified
into major groups: (M-) negative or (M+) positive thick
blood smear, for P. vivax or P. falciparum infection.
Next, rRNA gene-based nested PCR assay was per-
formed to identify P. vivax, P. falciparum or mixed
Figure 1 Rio Pardo settlement location. (A-B) The study took place in an agricultural settlement of Rio Pardo, in the northeast region of
Amazonas State, Brazil. (C) Main access of community of Rio Pardo is via a paved road (BR-174) that connects the states of Amazonas and
Roraima. (D) The settlement is comprised of households located along both sides of unpaved roads, which is a typical deforestation pattern in
the Amazon [33]. Rio Pardo outline by Sylvain JM Desmoulière – ILMD. (E) The temporal distribution of API of P. vivax in the Ramal and Igarapé
areas occurred in the period, with the rainy season well defined: the rainy season (November–May) and the dry season (June–October). The
annual mean temperature was 31°C and average annual rainfall was 2,000 mm per year. Arrow: indicates cross-sectional study period.
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were classified in minor subgroups: (PCR+/M-) positive
mixed or P. vivax PCR and negative Giemsa-stained
thick blood smears that showed no clinical symptoms of
malaria during the two months of follow-up; (PCR+/M+)
individuals positive for mixed or P. vivax PCR that were
positive P. vivax for Giemsa-stained thick blood smears at
cross sectional survey and had acute malaria. All subjects
received anti-malarial drugs according to the practical
guide for malaria treatment in Brazil [37]. (PCR-/M-)
negative individuals, who had no infection at cross sec-
tional survey and individuals who were PCR positive or
had malaria exclusively by P. falciparum were excluded
from the study. Over 360 days, a prospective study
was carried out and information about new malaria
infection by P. vivax was collected through SIVEP-
malaria database.
Sample collection and malarial infection diagnosis
Thick blood smears for malaria diagnosis were collected
and read by a local microscopist as recommended by the
Brazilian Ministry of Health [37]. The slides were sent toa central laboratory and reviewed by an experienced mi-
croscopist, who confirmed the diagnosis.
Five ml peripheral blood was harvested by vein punc-
ture, processed and stored at -20°C. DNA was extracted
using a QIAGEN kit according to the manufacturer’s
protocol. Electrophoresis was performed on a 0.6% agar-
ose gel in 0.5X TBE buffer to confirm successful DNA
extraction. Real-time PCR diagnoses were performed by
means of a multiplex reaction as described elsewhere
[38,39]. All primers and probes were purchased from
Applied Biosystems™. To discriminate between Plasmo-
dium species, probes were constructed using a VIC or
FAM dye flag for P. vivax or P. falciparum, respectively.
TAMRA quencher was used for both probes. For
standardization of the real-time PCR protocol, 30 mal-
aria negative and 50 malaria positive samples from the
FIOCRUZ-ILMD bank were used to optimize the test.
Recombinant protein production
The recombinant protein ICB2-5 (representing the
N-terminus of Pv-MSP1) comprises three conserved
blocks (Blocks 1, 3, and 5) and two variable blocks
Figure 2 Participant flow diagram. The 313 individuals included in the study were classified into major groups (M- or M+) and further sub
classified into three minor groups (PCR-/M-, PCR+/M- or PCR+/M+). For serology of total IgG and subclass, two patent P. falciparum mono-
infection (N = 2) and P. falciparum mono-infection by PCR (N = 3) were excluded. Three hundred eight samples from the minor groups were
used: PCR+/M- (N = 25), twenty five P. vivax infected individuals (three with mixed infections) had no malaria symptoms over two-month follow-
up. Fifteen subjects from the PCR+/M + group had acute malaria during the study. Two hundred sixty eight were uninfected (PCR-/M-) at cross
sectional. For subclass analysis, sera had sufficient amounts and that respond with total IgG anti ICB2-5 were evaluated, (N = 70) of PCR-/M-;
(N = 13) of PCR+/M- and (N = 8) PCR+/M + .
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strain as glutathione S-transferase (GST) fusion pro-
teins [27-30,33]. As a control, GST alone was also
produced. GST and P. vivax recombinant protein
were purified using glutathione-sepharose 4B col-
umns (Amersham Pharmacia), and protein concentra-
tion was determined by Bio-Rad Protein Assay Kit I
(Bio-Rad Laboratories, Inc) [27-30].
Humoral immune response analysis
Naturally acquired IgG antibodies against Pv-MSP1 have
been characterized elsewhere by ELISA [27]. Based on
individual values for OD against recombinant proteins,all tests were done in duplicate. Firstly the average OD
of ICB2-5 was calculated to exclude reactivity against
GST. For each individual, the GST cut offs were calcu-
lated as average OD of GST adding two Standard Devi-
ation (SD) values. Thus, a serum was considered positive
if ICB2-5 OD minus individual GST cut-offs was greater
than zero. Based on population variation against ICB2-5,
the ICB2-5 cut off were calculated as average OD of sera
samples adding two SD values from 20 healthy individ-
uals who had never suffered malaria.
Similarly, the positivity of serum to ICB2-5 was deter-
mined if the average OD of ICB2-5 was greater than
ICB2-5 cut off. For each IgG subclass the ICB2-5 cut off
Table 1 Summary of epidemiological results
Characteristic Result
Gender
Male (n(%)) 180 (59)
Female (n(%)) 124 (40.8%)
Total (n) 304*

















Never had malaria or didn’t know 37 (11.9%)
*information obtained trough interview, some individuals didn’t know
the information.
TR-Time of residence in Rio Pardo settlement, NI Number of previous
infections, LA Time in months since the last malaria attack, INF malaria
infection. We consider statistically significant p values lower than 0.05. The
differences in proportions were evaluated by chi-square (X
2) test. For analysis
between two continuous variable Spearman’s (SC).
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had never suffered malaria.
IgG subclasses were determined by ELISA using spe-
cific monoclonal antibodies for each isotype (Sigma, St.
Louis, MO, USA) as described [27,30]. All sera were
tested at dilutions of 1:100 in duplicate and monoclo-
nal antibody binding was detected with peroxidase-
conjugated anti-mouse immunoglobulin (Sigma).
Statistical methods
Statistical analysis was performed using The R Project
for Statistical Computing version 3.0.1. Normality was
tested by Kolmogorov-Smirnov test. Logistic regression
predicting positive vs. negative IgG anti ICB2-5 using
non-infected subjects (PCR-/M- group) as reference was
used to compare age, time of residence and time of last
malaria attack. Differences in total IgG and subclasses
levels were assessed between three groups (PCR-/M-;
PCR+/M + and PCR+/M-) by one-way nonparametric
Kruskal-Wallis test (first panel). Analysis to assess which
group total IgG and subclasses levels were different was
performed by non-parametric Dunn’s test for multiple
comparisons (second panel). The significant differences
(p < 0.05) were identified as letters “a” or “b”, intermedi-
ate level of antibodies was “ab”. The Kaplan-Meier sur-
vival analysis was performed to evaluate the probability
of P. vivax infection over one year follow-up period
(November 2008 to November 2009) between the ser-
ology groups negative and positive for ICB2-5. Indi-
viduals who were found infected in the cross-section
period using Giemsa-stained thick blood smears were
excluded from this analysis. P-values <0.05 were con-
sidered statistically significant.
Ethical procedures
The study was approved by the Research Ethical Com-
mittee of the Federal University of Amazonas (Ethical
Approval No. 3640.0.000.115-07). Informed written con-
sent was obtained from all participants. For those under
18 years old, parents were instructed about the objec-
tives of the study and signed together with the partici-
pant an informed consent. All patients tested positive in
the thick blood smear during the cross-sectional study
were treated according to the anti-malarial treatment
guidelines from the Brazilian Ministry of Health.
Results
Recruitment and participant flow
From a census of more than 500 residents followed
cross-sectional from September to November 2008, three
hundred thirteen residents met inclusion criteria to par-
ticipate of the current study. The epidemiological data
from this human population were recorded throughcross-sectional surveys and summarized in Table 1. A par-
ticipant flow diagram for the study is shown in Figure 2.
Giemsa-stained thick blood smears and rRNA gene-
based nested PCR assay to identify P. vivax, P. falcip-
arum or mixed (P. vivax and P. falciparum) infections
performed through cross-sectional surveys were summa-
rized in Table 2. When the subjects were stratified based
on diagnosis by thick blood smear (Figure 2), two hun-
dred ninety six individuals were negative (M-) and fif-
teen individuals had P. vivax malaria during cross
sectional survey (M+ P. vivax). Two individuals had
acute P. falciparum mono-infection and were excluded
(Figure 2).
After diagnosis by rRNA gene-based nested PCR assay
for P. vivax and P. falciparum, three individuals with P.
falciparum mono-infection (PCR P. falciparum +) were
excluded. From three hundred and eight individuals di-
agnosed by PCR, two hundred sixty eight individuals
were uninfected at cross sectional because they were
Table 2 Result for the methods used for diagnosis
PCR
Microscopy analysis
Negative Plasmodium vivax Plasmodium falciparum Mixed infection Total
Negative 268 (85.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 268 (85.6%)
P. vivax 22 (7.0%) 14 (4.4) 0 (0.0%) 0 (0.0%) 36 (11.5%)
P. falciparum 3 (1.0%) 0 (0.0%) 2 (0.6%) 0 (0.0%) 5 (1.6%)
Mixed infection 3 (1.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.2%)
Total 296 (94.5%) 15 (4.8%) 2 (0.6%) 0 (0.0%) 313 (100%)
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PCR (PCR-/M-).
Further subclassification indicated that acute P. vivax
infection was confirmed by microscopy examination and
PCR in the fifteen individuals (PCR+/M+) of which one
had acute P. vivax and P. falciparum infections. Twenty-
five individuals whose diagnosis of P. vivax infections
(which three with P. vivax and P. falciparum infections)
was seen only in nested-PCR (PCR+/M-) showed no
clinical symptoms of malaria over two-month follow-up
(Figure 2).
Assessing humoral response against the N-terminus of
Pv-MSP1
Acquisition of natural antibodies against the N-terminus
of Pv-MSP1 showed from all samples tested, one hun-
dred nine individuals responded with IgG anti ICB2-5
(109/308), summarized in Figure 3. Analysis revealed
that 66.6% of individuals from PCR+/M+ (10/15) res-
ponded to ICB2-5, whereas among the subjects who didFigure 3 Classification of the cross-sectional study. The
percentage of IgG responders to ICB2-5 were determined in 308
individuals classified into three minor groups (PCR+/M+, PCR+/M- or
PCR-/M-).not have malaria infection until cross sectional survey
(PCR-/M-), the frequency response was 32.0% (86/268).
Importantly, frequency of responders to ICB2-5 from
PCR+/M- was 52.0% (13/25) and slightly lower than
PCR+/M+ (not statistically significant).
Comparing the median of IgG anti ICB25 by one-way
non-parametric Kruskal-Wallis test, the levels of these
antibodies were different among the three groups tested
(Figure 4A). Using non parametric Dunn's test for mul-
tiple comparisonsto show differences as letters “a” or “b”
at p < 0.05, the PCR+/M- group had more IgG anti
ICB2-5 than uninfected individuals, whereas subjects
with acute malaria had an intermediate level of anti-
bodies “ab” (Figure 4B).
Using logistic regression to assess antibody predic-
tion into groups and epidemiological data (Table 3),
individuals of PCR+/M- had 2.45 more likely to have IgG
anti ICB2-5 than reference group, PCR-/M- (P = 0.036).
Analysing some epidemiological data, the presence of
IgG antibodies ICB2-5 was solely dependent on the
age (P = 0.003).
The subclass analysis was performed only those that
had sufficient amounts of serum (N = 91) and numbers
of tested sera for subclasses each group is shown in
Figure 2. The characterization of IgG subclass anti-
ICB2-5 as a whole revealed that IgG3 anti-ICB2-5 was
the most prevalent at 51.6% (47/91), IgG2 29.6% (27/91).
Both IgG1 and IgG4 subclasses comprised 8.7% (8/91)
each. When analyses were determined between groups,
the IgG3 frequencies were increased in PCR+/M- 84.6%
(11/13) and PCR+/M + 62.5% (5/8) and reduced 44.2%
(31/70) in the uninfected group (Figure 5). The IgG2
frequencies increased only in infected groups, PCR+/M-
61.5% (8/13) remaining the same in both groups
25.0% (2/8) in PCR+/M+ and 24.2% (17/70) in unin-
fected individuals (PCR-/M-). The frequencies of others
subclasses were low.
When the subclasses levels were assessed between
groups by one-way non-parametric Kruskal-Wallis test,
increased levels of IgG3 anti ICB2-5 in infected individ-
uals who did not develop symptoms (PCR+/M-) were
highlighted (Figure 6A). The non-parametric Dunn's
test for multiple comparisons confirmed that IgG3 anti
ICB2-5 levels in these individuals were significantly higher
Figure 4 Acquisition of IgG antibodies against the N-terminus of Pv-MSP1. (A) Comparison of median of IgG anti ICB25 of the three minor
groups is shown by one-way non-parametric Kruskal-Wallis test. (B) The mean level of IgG anti-ICB2-5 using non-parametric Dunn’s test for
multiple comparisons. Statistically differences in the mean antibody at p < 0.05 is shown as letters “a” or “b”. Intermediate level of antibodies is
shown as “ab”.
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uninfected (PCR-/M-).
Considering others IgG subclass, although there were
some differences in IgG2 response between PCR+/M-
vs. PCR-/M- (p = 0.0092) levels observed between groups
were very low (Figure 6B). And still, the mean levels of
IgG1 and IgG4 were not different in comparison bet-
ween groups (Figure 6C-D).
The prevalence of antibodies for ICB2-5 was analysed
as a determinant factor for protection against malaria at-
tacks in a one-year follow-up. To this, a Kaplan-Meier





PCR-/M-(Reference) 86 (81,13)# 181 (90,05)
PCR+/M- 13 (12,26) 12 (5,97)
PCR+/M+ 8 (6,60) 7 (3,98)
Age 37.65 ± 1.92 30.48 ± 1.35
Time of residence 9.0 ± 3.4 7.5 ± 4.1
Time of last malaria attack 2 ± 5.1 2 ± 3.1
Note: Variables of time (age time of residence and time of last malaria attack) are s
# in perenthesis: percentage per column.
‘*’ P-value < 0.05.
‘**’ P-value < 0.01.three individuals from 313 participants (Figure 7). The
total IgG anti ICB2-5 was detected to be an important
factor of protection against malaria vivax attacks (p =
0.029). Unlike the total IgG, the low number of positive
IgG3 anti ICB2-5 hampered survival analysis.Discussion
In the current study, antibody immune response against
Pv-MSP1 was evaluated from a cross-sectional survey
with 308 individuals living in hyperendemic areas.
Higher levels of IgG3 against ICB2-5, corresponding toG anti ICB2-5







hown in years according to Mean ± Standard Error.
Figure 5 Frequencies of responders with IgG subclasses to ICB2-5 between groups. The IgG subclasses profiles to ICB2-5 were evaluated in
ninety one individuals classified in three minor subgroups: PCR+/M- (N=13); PCR+/M+ (N=8) and PCR-/M- (N=70).
Figure 6 Analysis of IgG subclass in responders to ICB2-5. Differences in subclasses levels were assessed between groups. A) IgG3 levels
against ICB2-5 of individuals from PCR+/M-; PCR+/M + and PCR-/M- were compared by one-way non-parametric Kruskal-Wallis test (first panel) to
assess differences between groups. Analysis to assess which group the levels of IgG3 were different was performed by non-parametric Dunn's
test for multiple comparisons (second panel). The significant differences (p < 0.05) were identified as letters “a” or “b”, intermediate level of
antibodies was “ab”. The same analyses were performed for other subclasses levels against ICB2-5: B) IgG2; C) IgG1 and D) IgG4.
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Figure 7 Kaplan-Meier survival analyses. The survival analysis was performed with two hundred ninety three (N = 293), because fifteen
subjects who had acute malaria at cross sectional survey were excluded. For prospective study of 365-days individuals who responded with total
IgG anti ICB2-5 at cross sectional survey had lower malaria attacks (P = 0,019; Log Rank Test).
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in symptomless Plasmodium vivax-infected individuals.
Despite that recombinant ICB2-5 contains long stret-
ches of amino acids that are conserved among the
P. vivax haplotypes (Belem and Salvador), which ex-
plains the higher frequency of responders to this poly-
peptide in endemic areas in Brazil [20,27,29], it has been
well established that these antibodies primarily recognize
the variable domains (Blocks 2 and 4) of ICB2-5 [27,35].
However, Pv-MSP1 Block 2 is poorly immunogenic and
achievement of clinical protection may be dependent on
successive exposure of polymorphic blocks or eliciting
short-lived antibody responses that also require frequent
boosting as occurs in asymptomatic infections [35].
Investigation of total IgG response to the N-terminus
of Pv-MSP1 revealed no significant differences between
individuals of PCR+/M- and PCR+/M+. As both groups
represent respectively, contingents of infected persons
with parasitaemia undetectable in thick blood smears
and without clinical signs of malaria and those with
patent parasitaemia and clinical symptoms, these data
suggest that total IgG against the N-terminus of Pv-
MSP1 may not be the only predictor of clinical pro-
tection. Nonetheless, total levels of IgG against the
N-terminus of Pv-MSP1 were higher in individuals with-
out clinical symptoms of malaria, corroborating with
previous study [30]. Moreover, whereas here IgG totallevels were considered as a mean of PCR+/M- group, in
previous study IgG total levels were analysed separately
to each subject [30].
Analysis of antibody subclasses showed a stark differ-
ence in IgG3 levels of individuals from PCR+/M- in
comparison to those had acute malaria, suggesting that
higher levels of this subclass against the N-terminus of
Pv-MSP1 could be related to absence of symptoms of
malaria over two months of follow up. As parasitemia
levels are detected only by real-time PCR and absence of
symptoms of malaria does not allow determining since
when these individuals were infected, it can be inferred
that IgG3 dependent on continued exposure to the para-
site could also be associated with this immune status.
Association between IgG3 antibodies and clinical pro-
tection from malaria was previously reported for P. fal-
ciparum antigens, such as MSP142, MSP119, AMA-1,
MSP2 and MSP3 [22,23,40-44]. Similarly, IgG3 immune
response to P. falciparum MSP1 (N-terminus) was asso-
ciated with prolonged periods without malarial infection
[45]. Moreover, the presence of IgG3 against Block 2 of
Pf-MSP1 of the individuals would be held by asymp-
tomatic infection confers a protective effect for extended
periods [46]. IgG3 requires continuous stimulation to
maintain effective levels of protection since IgG3 acts dir-
ectly and indirectly to counter merozoite infection of red
blood cells through the activation of monocytes [47-49].
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cluding variants of the PfMSP1 Block-2, variants of the
MSP-2, PvMSP5 frequently recognized by short-lived,
species-specific antibodies [50-54]. It is possible that tan-
dem, repeated, epitope sequences influence the ability to
stimulate effective memory B-cell responses, unlike re-
sponses to antigens without repeat sequences (AMA1,
EBA175, MSP2 or MSP119), in which responses are gen-
erally by both IgG1 and IgG3 [40,41,43,44,46,55-58].
According to conservation theory, the IgG subclass may
be associated with the degree of conservation of the
antigen, with conserved antigens preferentially inducing
IgG1, and polymorphic antigens preferentially inducing
IgG3, particularly if they contain repetitive polymorphic
sequences [50].
The presence of high levels of IgG antibodies against
the N-terminus of Pv-MSP1 was previously shown in
asymptomatic individuals infected with P. vivax [30]. In
this present study, information of new malaria infections
was collected in Brazilian surveillance database over a
year confirmed the Kaplan-Meier survival analysis for
IgG total. However, the low number of positive IgG3
anti ICB2-5 hampered the Kaplan-Meier survival ana-
lysis for IgG3. Some factors could explain the lack of
association of IgG3 in the survival analysis. It has
been suggested that detectable levels of IgG3 may be
particularly short-lived due to more rapid clearance
of this subclass from the circulation [45,46,50,54].
There was a decay API related to P. vivax incidence
during the surveillance period (Figure 1E). And still,
the decrease in the number of positive IgG3 respon-
ders would be inherent to the immunoassay, even
using monoclonal antibodies commonly used in Brazilian
populations.
The immune status established by P. vivax sub-
patent infection and symptomless indicates that ICB2-5
(corresponding to haplotype Belem) may be a potential
candidate antigen to consider for malaria vaccine deve-
lopment. Based on study findings, optimal immunity
may require sustained high levels of IgG3 against po-
lymorphic malaria antigens, which may require special
strategies that need to be factored into the vaccine
development process.
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